Advertisement
Mr. Marth has 30 years of experience in the pharmaceutical industry,including nearly a decade with Teva, which is among the top 20 pharmaceuticalcompanies in the world and is the leading generic pharmaceutical company. Mr.Marth has served on GPhA's Board of Directors since 2005, most recently asVice Chair.
Advertisement
"We are very pleased to welcome Bill as GPhA's Chairman of the Board,"said Kathleen Jaeger, GPhA President and CEO. "2008 will be an extremely busyyear and we look forward to Bill's excellent leadership as we work to increaseconsumer access to safe, affordable generic medicines.
"We also would like to extend our heartfelt thanks to Bruce Downey for histwo years of outstanding service as chairman and for his dedication to theindustry."
The GPhA Board also elected Hal Korman, President, North America, MylanInc., as its Vice Chairman and re-elected Rosendo Ferran, Senior Consultant,New Chemic, Inc., to serve as its Secretary-Treasurer. Bernhard Hampl,President and CEO, Sandoz US, and Bruce Downey, Chairman and CEO, BarrPharmaceuticals Inc., will serve as at-large members on the Board's ExecutiveCommittee.
GPhA represents the manufacturers and distributors of finished genericpharmaceuticals, manufacturers and distributors of bulk active pharmaceuticalchemicals, and suppliers of other goods and services to the generic drugindustry. Unbranded and branded generics represent 65% of the totalprescriptions dispensed in the United States, but only 20% of all dollarsspent on prescription drugs. For more information about the industry, visithttp://www.gphaonline.org.
SOURCE Generic Pharmaceutical Association (GPhA)
